サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1770880

女性用避妊薬市場- 世界の産業規模、シェア、動向、機会、予測、避妊薬別、デバイス別、地域別、競合別、2020-2030年

Female Contraceptive Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Contraceptive Drugs, By Device, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 186 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.05円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

女性用避妊薬市場- 世界の産業規模、シェア、動向、機会、予測、避妊薬別、デバイス別、地域別、競合別、2020-2030年
出版日: 2025年07月14日
発行: TechSci Research
ページ情報: 英文 186 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

女性用避妊薬の世界市場規模は、2024年に150億1,000万米ドルとなり、2030年までのCAGRは6.24％で力強い成長が予測されています。

この市場には、意図しない妊娠を防ぎ、女性の生殖の自律を支援するために設計された多様な製品と機器が含まれます。避妊法の選択肢には、ピル、インプラント、パッチなどのホルモン法、バリア法、子宮内避妊器具（IUD）、緊急避妊薬などがあります。この分野は、家族計画、妊産婦死亡率の削減、女性の健康支援において、世界的に重要な役割を果たしています。リプロダクティブ・ヘルス（性と生殖に関する健康）に対する意識の高まり、ヘルスケアへのアクセスの向上、政府の支援策、社会規範の発展が需要を後押ししています。国連人口基金（UNFPA）の2022年版報告書によると、世界では毎年1億2,100万件近くの予定外妊娠が発生しており、効果的な避妊ソリューションの必要性が浮き彫りになっています。製品開発における革新と文化的態度の変化は、引き続き世界の市場拡大を後押ししています。

市場概要
予測期間 2026-2030
市場規模：2024年 150億1,000万米ドル
市場規模：2030年 214億1,000万米ドル
CAGR：2025年～2030年 6.24%
急成長セグメント 皮下避妊インプラント
最大市場 北米

市場促進要因

女性のエンパワーメント

主な市場課題

限られたアクセスと認知度

主な市場動向

副作用の少ないホルモン避妊薬

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の女性用避妊薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 避妊薬（経口避妊薬、避妊注射薬、局所避妊薬、殺精子剤）別
    • 器具別（女性用コンドーム、ペッサリーおよびキャップ、膣リング、避妊スポンジ、皮下避妊インプラント、子宮内避妊器具（IUCD）、その他）
    • 地域別
    • 企業別（2024）
  • 製品市場マップ
    • 避妊薬別
    • デバイス別
    • 地域別

第6章 北米の女性用避妊薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の女性用避妊薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン

第8章 アジア太平洋地域の女性用避妊薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国

第9章 南米の女性用避妊薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの女性用避妊薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 合併と買収
  • 製品上市

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Bayer AG
  • Mayer Laboratories Inc
  • Pfizer Inc
  • Mylan Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Organon & Co.
  • Agile Therapeutics Inc
  • Lupin Pharmaceuticals Inc
  • The Female Health Company
  • FUJI LATEX CO.,LTD.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 16167

The Global Female Contraceptive Market was valued at USD 15.01 billion in 2024 and is projected to witness strong growth with a CAGR of 6.24% through 2030F. This market includes a diverse range of products and devices designed to prevent unintended pregnancies and support reproductive autonomy for women. Contraceptive options include hormonal methods like pills, implants, and patches, as well as barrier methods, intrauterine devices (IUDs), and emergency contraceptives. The sector plays a key role in family planning, reducing maternal mortality, and supporting women's health globally. Growing awareness about reproductive health, increased healthcare accessibility, supportive government initiatives, and evolving social norms are propelling demand. According to the UNFPA's 2022 report, nearly 121 million unintended pregnancies occur globally each year, highlighting the critical need for effective contraceptive solutions. Innovation in product development and shifting cultural attitudes continue to strengthen market expansion worldwide.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 15.01 Billion
Market Size 2030USD 21.41 Billion
CAGR 2025-20306.24%
Fastest Growing SegmentSub-dermal Contraceptive Implants
Largest MarketNorth America

Key Market Drivers

Women's Empowerment

Women's empowerment is a major catalyst for growth in the female contraceptive market, influencing healthcare decision-making and reproductive autonomy. Educated and informed women are better equipped to make decisions regarding contraception that align with their health needs and personal circumstances. Greater empowerment improves access to healthcare services, prompting more women to utilize family planning clinics and seek out reliable contraceptive options. As economic independence grows, women are increasingly able to afford and prioritize contraceptive products and services. This economic and social empowerment drives demand, encouraging pharmaceutical companies to innovate and expand contraceptive offerings to meet diverse needs across different populations.

Key Market Challenges

Limited Access and Awareness

Limited access to and awareness of contraceptive options remains a major barrier in the global female contraceptive market, particularly in underprivileged and rural areas. Many women face financial, cultural, or geographic constraints that prevent them from obtaining reliable contraceptives. A lack of education and knowledge about available methods also contributes to low adoption rates. Addressing this challenge requires coordinated efforts by governments, NGOs, and international health organizations to expand education campaigns and improve access to family planning services. By empowering women with accurate information and affordable options, these initiatives aim to reduce disparities and foster informed reproductive choices.

Key Market Trends

Hormonal Contraceptives with Reduced Side Effects

A significant trend shaping the female contraceptive market is the development of hormonal contraceptives designed to minimize side effects. Manufacturers are investing in research to produce solutions that effectively prevent pregnancy while reducing issues such as mood changes, weight gain, and reduced libido. These innovations aim to enhance the user experience, making hormonal contraceptives more appealing and acceptable to a broader population. As awareness of long-term reproductive health grows, demand for safer, user-friendly options is driving the evolution of new-generation hormonal contraceptives with improved tolerability and efficacy.

Key Market Players

  • Bayer AG
  • Mayer Laboratories Inc
  • Pfizer Inc
  • Mylan Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Organon & Co.
  • Agile Therapeutics Inc
  • Lupin Pharmaceuticals Inc
  • The Female Health Company
  • FUJI LATEX CO.LTD.

Report Scope:

In this report, the Global Female Contraceptive Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Female Contraceptive Market, By Contraceptive Drugs:

  • Oral Contraceptives
  • Contraceptive Injections
  • Topical Contraceptives
  • Spermicides

Female Contraceptive Market, By Device:

  • Female Condoms
  • Diaphragms and Caps
  • Vaginal Rings
  • Contraceptive Sponges
  • Sub-dermal Contraceptive Implants
  • Intra Uterine Contraceptive Devices (IUCDs)
  • Others

Female Contraceptive Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Female Contraceptive Market.

Available Customizations:

Global Female Contraceptive market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Female Contraceptive Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 5.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Contraceptive Drugs
    • 5.3.2. By Device
    • 5.3.3. By Region

6. North America Female Contraceptive Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 6.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Female Contraceptive Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Contraceptive Drugs
        • 6.3.1.2.2. By Device
    • 6.3.2. Canada Female Contraceptive Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Contraceptive Drugs
        • 6.3.2.2.2. By Device
    • 6.3.3. Mexico Female Contraceptive Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Contraceptive Drugs
        • 6.3.3.2.2. By Device

7. Europe Female Contraceptive Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 7.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Female Contraceptive Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Contraceptive Drugs
        • 7.3.1.2.2. By Device
    • 7.3.2. United Kingdom Female Contraceptive Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Contraceptive Drugs
        • 7.3.2.2.2. By Device
    • 7.3.3. France Female Contraceptive Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Contraceptive Drugs
        • 7.3.3.2.2. By Device
    • 7.3.4. Italy Female Contraceptive Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Contraceptive Drugs
        • 7.3.4.2.2. By Device
    • 7.3.5. Spain Female Contraceptive Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Contraceptive Drugs
        • 7.3.5.2.2. By Device

8. Asia-Pacific Female Contraceptive Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 8.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Female Contraceptive Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Contraceptive Drugs
        • 8.3.1.2.2. By Device
    • 8.3.2. Japan Female Contraceptive Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Contraceptive Drugs
        • 8.3.2.2.2. By Device
    • 8.3.3. India Female Contraceptive Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Contraceptive Drugs
        • 8.3.3.2.2. By Device
    • 8.3.4. Australia Female Contraceptive Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Contraceptive Drugs
        • 8.3.4.2.2. By Device
    • 8.3.5. South Korea Female Contraceptive Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Contraceptive Drugs
        • 8.3.5.2.2. By Device

9. South America Female Contraceptive Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 9.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Female Contraceptive Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Contraceptive Drugs
        • 9.3.1.2.2. By Device
    • 9.3.2. Argentina Female Contraceptive Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Contraceptive Drugs
        • 9.3.2.2.2. By Device
    • 9.3.3. Colombia Female Contraceptive Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Contraceptive Drugs
        • 9.3.3.2.2. By Device

10. Middle East and Africa Female Contraceptive Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 10.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Female Contraceptive Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Contraceptive Drugs
        • 10.3.1.2.2. By Device
    • 10.3.2. Saudi Arabia Female Contraceptive Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Contraceptive Drugs
        • 10.3.2.2.2. By Device
    • 10.3.3. UAE Female Contraceptive Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Contraceptive Drugs
        • 10.3.3.2.2. By Device

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Bayer AG
    • 14.1.1. Business Overview
    • 14.1.2. Product Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Mayer Laboratories Inc
  • 14.3. Pfizer Inc
  • 14.4. Mylan Pharmaceuticals Inc
  • 14.5. Teva Pharmaceutical Industries Ltd
  • 14.6. Organon & Co.
  • 14.7. Agile Therapeutics Inc
  • 14.8. Lupin Pharmaceuticals Inc
  • 14.9. The Female Health Company
  • 14.10. FUJI LATEX CO.,LTD.

15. Strategic Recommendations

16.About Us & Disclaimer